These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36437230)

  • 1. Aminoglycoside induced ototoxicity risk in the cystic fibrosis population: The utility of large-scale screening.
    Lopes J; Vidal-Folch N; Lundquist P; Schimmenti LA; Demirel N; Dean V; Olson J; Auth T; Butz M; Reed K; Wylam M; Balcom J; Boczek NJ; Hasadsri L
    Pediatr Pulmonol; 2023 Mar; 58(3):819-824. PubMed ID: 36437230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
    Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
    J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a bedside test to detect genetic susceptibility to aminoglycoside-induced hearing loss: Has the future arrived?
    May ML; Osowicki J; Gaafar D; Suthers G
    J Paediatr Child Health; 2023 Jan; 59(1):9-11. PubMed ID: 36465032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
    Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
    J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides.
    Huang SP; McKinzie CJ; Tak CR
    J Manag Care Spec Pharm; 2021 Feb; 27(2):157-165. PubMed ID: 33506732
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.
    Veenstra DL; Harris J; Gibson RL; Rosenfeld M; Burke W; Watts C
    Genet Med; 2007 Oct; 9(10):695-704. PubMed ID: 18073583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
    Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
    J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.
    Handelsman JA; Nasr SZ; Pitts C; King WM
    Pediatr Pulmonol; 2017 Sep; 52(9):1157-1162. PubMed ID: 28737283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis.
    Elson EC; Meier E; Oermann CM
    J Cyst Fibros; 2021 Mar; 20(2):284-287. PubMed ID: 32811788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacogenomic MT-RNR1 Screening for Aminoglycoside-Induced Ototoxicity and the Post-Test Counseling Conundrum.
    Rigobello R; Shaw J; Ilg D; Zimmerman R; Edelmann L; Kornreich R; Scott SA; Cody N
    Clin Pharmacol Ther; 2023 Aug; 114(2):262-265. PubMed ID: 37314952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal hearing in a child with the m.1555A>G mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?
    Al-Malky G; Suri R; Sirimanna T; Dawson SJ
    Int J Pediatr Otorhinolaryngol; 2014 Jun; 78(6):969-73. PubMed ID: 24703164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
    Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
    J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.
    O'Donnell EP; Scarsi KK; Scheetz MH; Postelnick MJ; Cullina J; Jain M
    Int J Antimicrob Agents; 2010 Jul; 36(1):94-5. PubMed ID: 20382508
    [No Abstract]   [Full Text] [Related]  

  • 15. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
    McRorie TI; Bosso J; Randolph L
    Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacist-administered audiology screening for pediatric cystic fibrosis patients exposed to high-dose aminoglycosides: A pilot study.
    McKinzie CJ; Kam CW; Parry R; Darby M; Tak CR
    Pediatr Pulmonol; 2022 Jul; 57(7):1814-1817. PubMed ID: 35485261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.
    Gleser MA; Zettner EM
    Int J Audiol; 2018 Dec; 57(12):917-924. PubMed ID: 30382794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is deafness mutation screening required in cystic fibrosis patients?
    Abusamra R; McShane D
    Paediatr Respir Rev; 2016 Aug; 20 Suppl():24-6. PubMed ID: 27427311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.
    Garinis AC; Poling GL; Rubenstein RC; Konrad-Martin D; Hullar TE; Baguley DM; Burrows HL; Chisholm JA; Custer A; Hawe LD; Hunter LL; Marras TK; Ortiz CE; Petersen L; Steyger PS; Winthrop K; Zettner EM; Clark K; Hungerford M; Vachhani JJ; Brewer CC
    Am J Audiol; 2021 Oct; 30(3S):800-809. PubMed ID: 34549989
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.